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Continuous biomanufacturing provides many important strategic advantages for the production of protein 
therapeutics through process integration, simplification and intensification. To achieve upstream process 
intensification, Sanofi is currently developing robust cell culture processes that can achieve ultra-high cell 
densities and productivities (“push to high”) while minimizing cell-specific perfusion rates (“push to low”). We 
have applied ATF perfusion technology and improved the cell culture environment to achieve high cell densities 
and volumetric productivities with minimal ATF filter fouling. Meanwhile, we have employed high-throughput 
screening strategies to increase medium depth and reduce medium requirements. We will describe results as 
well as ongoing efforts to further intensify this continuous cell culture platform and realize even more of its 
significant upward potential. 
 
Continuous biomanufacturing also has the potential to deliver robust, steady-state product quality, resulting in 
enormous operational flexibility. Instead of traditionally defining batches by unit operation, product can be 
batched in time (first-in, first-out), removing downstream processing constraints and minimizing production cycle 
times. In this presentation, we use both theoretical models and experimental data to evaluate the effects of 
perfusion on product quality, considering the impact of perfusion-specific controllable parameters (e.g., 
perfusion rate, bleed rate, target viable cell density) on product quality. We also compare and contrast product 
quality attributes between perfusion and fed-batch processes and examine the feasibility of maintaining a 
process and product quality at steady state while presenting relevant, real-world case studies. 
